Sugi Predict

Sugi Predict / Compounds / SCHEMBL23930611

SCHEMBL23930611

SCHEMBL23930611

Nc1nc(Nc2ccc(F)c(F)c2)sc1C(=O)c1cc(C(=O)O)no1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CCNA2 P20248 5/20 0.50
▸ CDK2 P24941 5/20 0.50
▸ MAPT P10636 8/20 0.49
▸ MEN1 O00255 4/20 0.49
▸ KMT2A Q03164 4/20 0.49
▸ CHRNA7 P36544 1/20 0.49
▸ CDK5 Q00535 7/20 0.48
▸ CDK5R1 Q15078 7/20 0.48
▸ TP53 P04637 2/20 0.48
▸ LMNA P02545 1/20 0.48
▸ NPC1 O15118 3/20 0.47
▸ RAB9A P51151 2/20 0.47
▸ GSK3A P49840 1/20 0.46
▸ GSK3B P49841 1/20 0.46
▸ MAPK14 Q16539 1/20 0.46
▸ TDP1 Q9NUW8 1/20 0.46
▸ POLB P06746 1/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31633457 1.00 CCNA2 (0.50) CCNA2CDK2MAPTMEN1KMT2A
SCHEMBL30210844 0.90 DHODH (0.53) CCNA2CDK2MAPTMEN1KMT2A
SCHEMBL23930511 0.89 CCNA2 (0.60) CCNA2CDK2MAPTMEN1KMT2A
SCHEMBL31633449 0.86 DHODH (0.56) MAPTMEN1KMT2ACHRNA7TP53
SCHEMBL23930620 0.86 DHODH (0.56) MAPTMEN1KMT2ACHRNA7TP53
SCHEMBL23930591 0.84 MAPT (0.45) CCNA2CDK2MAPTMEN1KMT2A
SCHEMBL30210963 0.84 MAPT (0.45) CCNA2CDK2MAPTMEN1KMT2A
SCHEMBL23930636 0.83 CHRNA7 (0.44) CCNA2CDK2MAPTMEN1KMT2A
SCHEMBL23930533 0.83 CHRNA7 (0.46) CCNA2CDK2MAPTMEN1KMT2A
SCHEMBL30210973 0.83 CHRNA7 (0.46) CCNA2CDK2MAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4139287-B1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION BAYER AG (DE) 2025-02-26 — — EP disclosed
US-20230167103-A1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION BAYER AKTIENGESELLSCHAFT (DE) 2023-06-01 — — US disclosed
US-20230167103-A1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION BAYER AKTIENGESELLSCHAFT (DE) 2023-06-01 — — US disclosed
US-20230167103-A1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION BAYER AKTIENGESELLSCHAFT (DE) 2023-06-01 — — US disclosed
EP-4139287-A1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION Bayer Aktiengesellschaft (DE) 2023-03-01 — — EP disclosed
CN-115697979-A Substituted aminothiazoles as DGKZETA inhibitors for immune activation 拜耳公司 2023-02-03 — — CN disclosed
WO-2021214020-A1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION BAYER AKTIENGESELLSCHAFT (DE) 2021-10-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230167103-A1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION DGKZ, DGKA, DGKG CCNA2 836/4885CDK2 232/4885MAPT 3251/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.